GE Healthcare announced on Wednesday that Nanotherapeutics, Inc., selected GE Healthcare Life Sciences' Flex Factory biomanufacturing platform for use in its Advanced Development and Manufacturing Center.
Construction on the NANO-ADM is expected to be completed in 2015, and will fulfill a 2013 U.S. Department of Defense contract to enable faster and more effective biomedical countermeasure development. The countermeasures will be designed to protect and treat military personnel against chemical, biological, radiological and nuclear attacks, as well as infectious diseases.
Nanotherapeutics' use of the biomanufacturing platform and single-use technologies will reduce processing time and allow rapid reconfiguration of the facility, which enables manufacturing of different products.
"We are delighted to be playing a pivotal role in the establishment and set-up of Nanotherapeutics' Advanced Development and Manufacturing Center," BioProcess Vice President and GE Officer Nigel Darby said. "The wide-ranging and forward-looking criteria of this U.S. Department of Defense contract demands a fast and responsive solution and the flexibility of our established FlexFactory manufacturing platform and the deep sector experience of our team will both be critical components in the success of the program. Being selected by the industry experts at Nanotherapeutics is a clear indication of our reputation as a trusted partner in technologies for biopharmaceutical manufacturing and in process development."